Novel Polymers for Cell Encapsulation

用于细胞封装的新型聚合物

• 批准号: 6550167
• 负责人: MANSSUR YALPANI
• 金额: $ 28.76万
• 依托单位: CARBOMER, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-01 至 2003-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6550167
• 关键词: cell sorting; cell transplantation; chemical synthesis; cytology; drug delivery systems; insulin; insulin dependent diabetes mellitus; microcapsule; polyglutamates; polymers; technology /technique development; tissue /cell preparation

DESCRIPTION (provided by applicant): The incidence of diabetes mellitus in adults is on the rise globally and constitutes a major health problem. We are proposing the development of a new encapsulated glucose-responsive insulin secreting cell implants for the treatment of type I diabetes, using poly(gamma-glutamic acid) (gamma-PGA). Previously unavailable, very high molecular weight gamma-PGA will be prepared, using a proprietary process. Preliminary data from pilot studies indicate that gamma-PGA constitutes a promising material and viable approach for efficacious and prolonged insulin delivery in therapeutic uses. PROPOSED COMMERCIAL APPLICATIONS: Diabetes mellitus constitutes a major health problem. Diabetes can lead to many complications, e.g., lower extremity ulcers, visual dysfunctions, and impaired wound healing. About 90% of the costs of diabetes therapy are spent on diabetes communications. Over $11 billion is spend on end-stage renal disease treatment alone. Successful development of insulin-PGA delivery systems will have a major impact on diabetes therapy. Achieving the preparation of biocompatible PGA for cell encapsulation will constitute a major milestone in the use of biopolymers.

描述（由申请人提供）：糖尿病在全球成人中的发病率呈上升趋势，并构成一个主要的健康问题。我们正在提议开发一种新的封装葡萄糖反应胰岛素分泌细胞植入物，用于治疗I型糖尿病，使用聚γ -谷氨酸（γ - pga）。以前不可用的，非常高分子量的γ - pga将使用专有工艺制备。试点研究的初步数据表明，γ - pga是一种有前途的材料和可行的方法，可用于有效和延长治疗用途的胰岛素输送。